

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of

**Complete if Known**

Application Number	09/842,547
Filing Date	April 26, 2001
First Named Inventor	
Art Unit	4614 1616
Examiner Name	John D. Pak
Attorney Docket Number	10692V-000520US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	International Search Report for PCT/CA 01/00566 filed 4/26/01	
	AB	SUMITANI et al., Cytotoxic Effect of Sodium Nitroprusside on Cancer Cells: Involvement of Apoptosis and Suppression of C-MYC and C-MYB Proto-Oncogene Expression, Anticancer Research 17:865-872 (1997), XP-001064190	
	AC	UMANSKY et al., Nitric Oxide-Mediated Apoptosis in Human Breast Cancer Cells Requires Changes in Mitochondrial Functions and is Independent of CD95 (APO-1/Fas), International Journal of Oncology 16:109-117 (2000), XP-001064253	
	AD	UMANSKY et al., Activated Endothelial Cells Induce Apoptosis in Lymphoma Cells: Role of Nitric Oxide, International Journal of Oncology 10: 465-471 (1997) XP-001064191	
	AE	DOOKERAN et al., Mechanisms of Antitumor Activity for Sustained-Release Nitric-Oxide Donor, Nitroprusside in Ethiodol, #1782, Cook County Hospital, Chicago, IL, XP-001064169	

Examiner  
SignatureDate  
Considered

6/13/03

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
WC 9054823 v1



PTO/SB/081 (10-01)  
Approved for use through 10/31/2002. OMB 033-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **2**

Complete if Known

Application Number	09/842,547
Filing Date	April 26, 2001
First Named Inventor	Adam, et al.
Art Unit	<del>4614</del> 1616
Examiner Name	John D. Pak
Attorney Docket Number	10692V-000520US

RECEIVED  
APR 15 2003  
TECH CENTER 1600/2900

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	AA	US-5,434,256	07/18/1995	Khokhar, Abdul R., et al.	
	AB	US-6,171,620 B1	01/09/2001	Piver, M. Steven, et al.	
	AC	US-6,235,782 B1	05/22/2001	Pamukcu, Rifat, et al.	
	AD	US-5,849,790	12/15/1998	Palmer, Jay W., et al.	
	AE	US-2002/0010146 A1	01/24/2002	Garvey, David S., et al.	
	AF	US-6,103,275	08/15/2000	Seitz, William A., et al.	
	AG	US-US 2001/0038832 A1	11/08/2001	Bonavida, Benjamin	
	AH	US-6,270,779 B1	08/07/2001	Fitzhugh, Anthony L., et al.	
	AI	US-6,153,186	11/28/2000	Stamler, Jonathan S., et al.	
	AJ	US-6,180,824 B1	01/30/2001	Stamler, Jonathan S., et al.	
	AK	US-6,057,367	05/02/2000	Stamler, Jonathan S., et al.	
	AL	US-6,203,789 B1	03/20/2001	Stamler, Jonathan S., et al.	
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-			
	AT	US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AU		00/51597 WO	09/08/2000	Ouellet, et al.		<input type="checkbox"/>
	AV		01/70199 WO	09/27/2001	Zhao, et al.		<input type="checkbox"/>
	AW		98/13358 WO	04/02/1998	Saavedra, et al.		<input type="checkbox"/>
	AX		99/33823 WO	07/08/1999	Towart, Robertson		<input type="checkbox"/>
	AY		01/54771 A2 WO	08/02/2001	Black, et al.		<input type="checkbox"/>
	AZ		99/57306 WO	11/11/1999	Adams, et al.		<input type="checkbox"/>
	BA						<input type="checkbox"/>
	BB						<input type="checkbox"/>

Examiner  
Signature


Date  
Considered

6/13/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
WC 9055750 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2**Complete if Known**

Application Number	09/842,547
Filing Date	April 26, 2001
First Named Inventor	Adams, et al.
Art Unit	<del>1614</del> 1616
Examiner Name	John D. Pak
Attorney Docket Number	10692V-000520US

**RECEIVED**  
APR 15 2003  
TECH CENTER 1600/2900**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BC	ELEY, K.W., et al., "THE EFFECTS OF PENTOXIFYLLINE ON THE SURVIVAL OF HUMAN GLIOMA CELLS WITH CONTINUOUS AND INTERMITTENT STEREOTACTIC RADIOSURGERY IRRADIATION"; Int. J. Radiation Oncology. Biol. Phys. (2002) Vol. 54, No. 2, pp 542-550	
	BD	KIM, et al., "TYPE 4 CYCLIC ADENOSINE MONOPHOSPHATE PHOSPHODIESTERASE AS A THERAPEUTIC TARGET IN CHRONIC LYMPHOCYTIC LEUKEMIA", Blood, (October 1, 1998), Vol. 92, No. 7, pp. 2484-2494	
	BE	YP, et al., "TOPICAL APPLICATIONS OF CAFFEINE OR (-)-EPIGALLOCATECHIN GALLATE (EGCG) INHIBIT CARCINOGENESIS AND SELECTIVELY INCREASE APOPTOSIS IN UVB-INDUCED SKIN TUMORS IN MICE", Proc. Nat'l Acad. Sci USA (Sept. 27, 2002) (19): 12455-12460, (Abstract only)	
	BF	CARDUCCI, et al., "EFFECT OF ENDOTHELIN-A RECEPTOR BLOCKAGE WITH ATRASENTAN ON TUMOR PROGRESSION IN MEN WITH HORMONE-REFRACTORY PROSTATE CANCER: A RANDOMIZED, PHASE II, PLACEBO-CONTROLLED TRIAL", Jour. of Clinical Oncology, (February 15, 2003), Vol. 21, No. 4, pp. 679-689.	
	BG	MARSHALL, et al., "NITROSATIVE STRESS-INDUCED APOPTOSIS THROUGH INHIBITION OF NF-KB", Jour. of Biological Chem., (Sept. 13, 2002), Vol. 277, No. 37, pp. 34223-34228.	
	BH	CHEN, et al., "IDENTIFICATION OF THE ENZYMATIC MECHANISM OF NITROGLYCERIN BIOACTIVATION", PNAS, (June 11, 2002), Vol. 99, No. 12, pp. 8306-8311.	
	BI	SUN, et al., "CYSTEINE-3635 IS RESPONSIBLE FOR SKELETAL MUSCLE RYANODINE RECEPTOR MODULATION BY NO", PNAS, (Sept. 25, 2001), Vol. 98, No. 20, pp. 11158-11162	
	BJ	MANNICK, et al., "FAS-INDUCED CASPASE DENITROSYLATION", Science, (April 23, 1999), Vol. 284, pp. 651-654.	
	BK	MARSHALL, et al., "EXHALED NITRIC OXIDE (NO), NO SYNTHASE ACTIVITY, AND REGULATION OF NUCLEAR FACTOR (NF) - KB", Am. J. Respir. Cell Mol. Biol., (1999), Vol 21, pp. 296-297	
	BL	STIX, GARY, "SAYING YES TO NO", Scientific American, (November 2001), pp. 34	
	BM		

Examiner  
SignatureDate  
Considered

6/13/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
WC 9055750 v1